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Summary The diaminocyclohexane platinum (Pt(DACH)) derivatives ormaplatin and oxaliplatin have caused severe and dose-limiting
peripheral sensory neurotoxicity in a clinical trial. We hypothesized that this toxicity could vary in relation to the biotransformation and
stereochemistry of these Pt(DACH) derivatives. We prepared pure R,R and S,S enantiomers of ormaplatin (Pt(DACH)CI4). oxaliplatin
(Pt(DACH)oxalato) and their metabolites (Pt(DACH)CI2 and Pt(DACH)methionine) and assessed their peripheral sensory neurotoxicity and
tissue distribution in the rat and in vitro anti-tumour activity in human ovarian carcinoma cell lines. The R,R enantiomers of Pt(DACH)CI4,
Pt(DACH)oxalato and Pt(DACH)CI2, induced peripheral sensory neurotoxicity at significantly lower cumulative doses (18 ± 5.7 vs
32 ±2.3 imol kg-1; P< 0.01) and at earlier times (4± 1 vs 6.7 ± 0.6 weeks; P= 0.016) during repeat-dose treatment than the S,Senantiomers.
Pt(DACH)methionine enantiomers showed no biological activity. There was no difference between Pt(DACH) enantiomers in the platinum
concentration in sciatic nerve, dorsal root ganglia, spinal cord, brain or blood at the end of each experiment. Three human ovarian carcinoma
cell lines (41M, 41McisR and SKOV-3) showed no (or inconsistent) chiral discrimination in theirsensitivity to Pt(DACH) enantiomers, whereas
two cell lines (CH-1 and CH-1cisR) showed modest enantiomeric selectivity favouring the R,R isomer (more active). In conclusion, Pt(DACH)
derivatives exhibit enantiomeric-selective peripheral sensory neurotoxicity during repeated dosing in rats favouring S,S isomers (less
neurotoxic). They exhibited less chiral discrimination in their accumulation within peripheral nerves and in vitro anti-tumour activity.
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The diaminocyclohexane platinum (Pt(DACH)) derivatives are
promising anti-tumour agents with two chiral centres in the DACH
ring and three possible isomeric forms (Kidani et al, 1978;
Anderson et al, 1986). They exhibit activity against cisplatin-resis-
tant tumours, but the development of early examples was limited
by their poor water solubility and stability (Burchenal et al, 1977).
Ormaplatin (formerly known as tetraplatin) and oxaliplatin have
been developed as more stable and water-soluble Pt(DACH)
derivatives and have recently entered clinical trials. A racemic
mixture oformaplatin (R,R and S,S enantiomers ofPt(DACH)Cl4)
was used because of limited differences between isomers in their
solubility, stability and anti-tumour activity (Anderson et al,
1986). Clinical trials of ormaplatin were recently abandoned
because of severe and dose-limiting peripheral neurotoxicity,
causing sensory ataxia and walking difficulties in some patients
that was related to the cumulative dose (Schilder et al, 1994).
Clinical trials of oxaliplatin, the pure R,R enantiomer of
Pt(DACH)oxalato, have also been associated with severe periph-
eral neurotoxicity (Extra et al, 1990) but interest remains high
because ofthis compound's activity in advanced colorectal cancer
when combined with 5-fluorouracil and folinic acid using
chronomodulated dosing (Levi et al, 1992). The mechanism(s)
underlying the peripheral neurotoxicity of ormaplatin and oxali-
platin in humans remain unclear.
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Anti-tumour platinum(IV) complexes are thought to elicit
biological effects by reduction to Pt(II) species and ligand
exchange reactions with biological macromolecules (Borch, 1987;
Eastman, 1987). Ormaplatin is known to undergo transformation in
biological systems (Figure 1) to Pt(DACH)CI2 with the loss oftwo
chloride atoms (Gibbons et al, 1989; Chaney et al, 1990; Carfagna
et al, 1991). The Pt(DACH)CI2 metabolite and its monoaquated
derivative, [Pt(DACH)Cl]H2O+, are the major platinum-containing
products present within the first few hours after ormaplatin treat-
ment (Mauldin et al, 1988; Carfagna et al, 1991), and later
Pt(DACH)methionine and the free DACH ligand are the major
species present in body fluids (Carfagna et al, 1991; Petros et al,
1994). Oxaliplatin the pure R,R enantiomer of Pt(DACH)oxalato,
is also transformed to Pt(DACH)C12 in biological systems
(Pendyala and Creaven, 1993). In this way, ormaplatin and oxali-
platin are associated with the generation of an array of potentially
bioactive platinum complexes after being given to human subjects.
The biotransformation products of other heavy metal complexes,
e.g. methyl mercury, have exhibited strong neurotoxicity in man
(Clarkson, 1993).
Many therapeutic drugs in clinical use are racemic mixtures, yet it
is well established that individual enantiomers may exhibit very
different pharmacokinetic or pharmacodynamic properties (Drayer
1986). Previous studies of the stereoselective action of Pt(DACH)
derivatives have indicated small and inconsistent differences
between isomers in anti-tumour activity, and that the degree and
direction ofanti-tumourchiral discrimination varies between tumour
*Formerly ofThe Institute ofOncology, Prince ofWales Hospital, Randwick,
NSW 2031, Australia
502Neurotoxicity ofPt(DACH) derivatives 503
Pt(rac-DACH)CI4 (ormaplatin)
Cl NH2\I/cI
Pt/
NH2 1/ \C
t112 3 s
NH2
NH2
Pt(R,R-DACH)oxalato (oxaliplatin)
t1/2 =12-15 min
Cl
Pt/
/ \CI
DACH ligand
NH3
NH3
Pt(DACH)methionine
COOH
NH2 NH2
\
Pt
/
NH2 C
CHl3
t,12=5h
NH2 Cl
S/ \ \
Binds to proteins
Binds to DNA
Other metabolites, e.g. Pt(DACH)
complexes of cysteine, orthinine,
urea and citrate
Figure 1 Putative biotransformation pathways of ormaplatin and oxaliplatin (Carfagna et al, 1991; Chaney et al, 1990; Pendyala and Creaven, 1993; Gibbons et
al, 1989; Maudlin et al, 1988; Petros et al, 1994)
models (Kidani et al, 1978; Vollano et al, 1987; Kido et al, 1993;
Siddik et al, 1993). We hypothesized that the peripheral sensory
neurotoxicity oformaplatin and oxaliplatin could vary in relation to
the enantiomeric configuration ofthe DACH ligand and their exten-
sive biotransformation. We prepared a series of pure R,R and S,S
enantiomers ofPt(DACH)Cl4, Pt(DACH)oxalato, Pt(DACH)C12 and
Pt(DACH)methionine with the specific aim ofassessing the periph-
eral sensory neurotoxicity of these Pt(DACH) enantiomers and
metabolites during repeated dose treatment in the rat. This model is
the only convenient way of studying platinum-induced peripheral
neurotoxicity at this time and shows similardrug-induced functional
and morphological changes (De Koning et al, 1987; Cavaletti et al,
1992) as humans (Thompson et al, 1984). Other workers have
shown that the metabolism and pharmacokinetics of Pt(DACH)
complexes is similar in rats and man (Carfagna et al, 1991; Petros et
al, 1994). Wedeveloped an ICP-MS method forplatinumanalysis of
rat neural tissue with the specific aim ofassessing the distribution of
platinum in rats in relation to the differential neurotoxicity of
Pt(DACH) derivatives. We found enantiomeric-selective peripheral
sensory neurotoxicity ofPt(DACH) derivatives favouring S,S enan-
tiomers (less toxic) but less chiral discrimination in their in vitro
anti-tumour activity against human ovarian carcinoma cell lines.
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MATERIALS AND METHODS
Preparation and characterization of platinum
complexes
Trans-1,2-diaminocyclohexane, (+)- and (-)-tartaric acids, potas-
sium tetrachloroplatinate(II), chlorine gas and d6-dimethyl
sulphoxide were obtained from Aldrich Chemical (AR grade).
Potassium iodide and silver nitrate were obtained from Rhone-
Poulenc and Deak International respectively. Dipotassium oxalate-
1-water was obtained from Merck. L-methionine was obtained from
BHP Chemicals. Nuclear magnetic resonance (NMR) experiments
were carried out on a Bruker AC200 spectrometer, using d6-
dimethyl sulphoxide as solvent. Infrared spectra were obtained on
Bio-rad FTS-Bruker IFS66V spectrometers as potassium bromide
and polyethylene discs respectively. Optical activity ofthe resolved
tartrate salts of 1,2-diaminocyclohexane was measured on a PolAAr
2001 polarimeter at 24°C using the sodium D line at
589 nm, in which water was used as the solvent and the concentra-
tion was 1 g 100 ml-'. The two hands of tartaric acid were used to
effect separation by fractional crystallization of the enantiomers of
trans-1,2-diaminocyclohexane. The tartrate salts ofthe enantiomers
were recrystallized from boiling water (10 ml g-' solid) to constant
[AID values of +11.5 (R,R) and -12.0 (S,S). The diamines were
recovered immediately before use by adding 10 M sodium
hydroxide to the suspension of their corresponding tartrate salts in
water until the pH reached 14, followed by extraction with
dichloromethane, drying over anhydrous sodium sulphate, filtration
and solvent removal at reduced pressure at 40°C. R,R and S,S-
dichloro-DACH-Pt(II) were prepared using a modified version of
the method ofDhara (1970), in which ammonia was replaced by the
resolved DACH diamines. '3C-NMR (DMSO-d6): 62.7 (C1,2), 31.3
(C36), 24.1 (C4,5) p.p.m. (Hoeschele et al, 1988). IR (cm-'): NH2
3277s, 3186 s, 3104 m; and NH2 756 s; (Kidani et al, 1978) s(Pt-Cl)
310. The oxidation ofdichloro-DACH-Pt(II) to tetrachloro-DACH-
Pt(IV) was achieved using hydrogen peroxide. The products were
confirmed by the shift ofs(Pt-Cl) to higher wave number (342 cm-1)
in their IR spectra. R,R- and S,S-oxalato-DACH-Pt(II) were
prepared and recrystallized according to the method of Kidani et al
(1978). '3C-NMR (DMSO-d6): 61.8 (C1,2), 31.5 (C3,6), 24.1 (C4,5),
165.9 (C = 0) p.p.m. (Kidani et al, 1978). IR NH2 3156, 3062 s;
-NH2 m; C =0 1708 s, 1674 s; C = O 1395 s (Hoeschele etal, 1988).
R,R- and S,S-methionine-DACH-Pt(II) were prepared using the
method ofMaudlin with some modification (Appleton et al, 1988).
Animals and drug administration
For each experiment, 36 age-matched inbred female Wistar rats
born within 1 week were allocated to treatment or control groups
of 12 animals each. Animals were first allowed to acclimatize for
2 weeks. They were 10 weeks old and weighed 210-240 g at the
start ofthe experiment. DACH complexes were dissolved in sterile
0.9% (v/v) sodium chloride by vortex mixing and sonication at an
injection volume of 10 ml kg-'. They were given by intraperitoneal
injection at intervals of 3-4 days (twice a week) for a total of 8
weeks. Control animals received the drug vehicle at the same
injection volume and frequency. Animals were weighed twice a
week and checked for signs oftoxicity daily. Any animals showing
signs of distress were immediately and painlessly killed. Animals
had continuous access to food and drinking water. The local
animal ethics committee approved the work.
Neurotoxicity assessment
Sensory nerve conduction velocity was calculated from recordings
of the evoked H-plantar response before and once a week during
treatment as described previously (De Koning et al, 1987;
McKeage et al, 1994) 72 h after platinum drug administration.
Hypnorm (fluanisone 10 mg ml-1, fentanyl citrate 0.3 mg ml-'.
Jansen Pharmaceuticals, Sydney, Australia) diluted 1:1 with sterile
water given by intramuscular injection provided light anaesthesia.
Responses were evoked by a 0.05-ms square wave in the sciatic
nerve at the sciatic notch and the tibial nerve at the ankle ofthe left
hind limb using percutaneous needle electrodes. H- and M-waves
were recorded via a pair of superficial silver-silver chloride elec-
trodes applied to the sole and dorsum of the hind paw. H-response
related sensory nerve conduction velocity was calculated by
dividing the distance between the stimulation site at the sciatic
notch and ankle (mm) by the difference in H-responselatency after
stimulation at the ankle and sciatic notch (ms). Differences
between the means of the control and treatment groups were
assessed using a t-test. A P-value of less than 0.025 was regarded
as significant as the mean control data were compared twice. The
onset ofneurotoxicity was defined as the development ofa statisti-
cally significant difference in mean sensory nerve conduction
velocity between the control and treatment groups. The time and
cumulative dose to the development of neurotoxicity with
Pt(DACH) enantiomers were compared.
Platinum analysis by inductively coupled plasma mass
spectrometry
Blood and tissues (brain, dorsal root ganglia, spinal cord and
sciatic nerve) were collected 7 days after the last treatment in order
to avoid sampling tissues at times when tissue platinum concentra-
tions can vary widely (Siddik et al, 1988). Whole blood and blood
plasma were prepared for platinum analysis by 1:25 dilution with
lysis buffer (0.1% NH4EDTA, 0.1% Triton X-1)00 in 2.5% ammo-
nium hydroxide). Tissues were digested overnight in 1 ml of 70%
nitric acid at room temperature then heated at 95'C until dry. The
residue was suspended in 1 ml of water and diluted with 0.1%
nitric acid and 0.1% Triton X-100. The samples were analysed for
platinum content using a Perkin Elmer Sciex Elan 5000 induc-
tively coupled plasma mass spectrometer. Platinum was read at
mass 195 with a dwell time of 100 ms and replicate time of
6000 ms. Calibration curves for standards ranging from 0.5 to
100 jg 1-1 in 0.1% nitric acid, whole blood, blood plasma, brain,
spinal cord, dorsal root ganglia or sciatic nerve had correlation
coefficients of > 0.96. Recovery of platinum from whole blood
and plasma was 100%. Recovery of platinum from tissues was >
80%. Detection limits were as follows: whole blood 0.012 gg 1-';
blood plasma 0.02 gg 1-', dorsal root ganglia 1.1 ng g-'; brain
0.29 ng g-1; spinal cord 0.06 ng g-1; and sciatic nerve 0.22 ng g- .
Intra-assay variability was < 5% and interassay variability < 6%.
Cell lines and cytotoxicity assessment
Human ovarian carcinoma cell lines were kindly provided by Dr
Lloyd Kelland. Their biological properties have been described
previously (Hills et al, 1989; Kelland et al, 1992). Cell lines were
grown as monolayers in Dulbecco's modified Eagle medium plus
10% fetal calf serum, 100 jig ml-' streptomycin, 100 units ml-1
penicillin and 2 mM L-glutamine in a 5% carbon dioxide-95% air
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Figure 2 Peripheral neurotoxicity of Pt(DACH)CI4 enantiomers in the rat. Age-matched rats were treated with R,R (A) or S,S (U) isomers of Pt(DACH)CI4 or
allocated to control treatment (0) with drug vehicle twice a week for 8 weeks. H-reflex related sensory nerve conduction velocity (m s-') was assessed once a
week (A and C), and body weights were recorded twice a week (B and D). The symbols represent the mean and the bars the standard error of the mean for
groups of 12 rats. The asterisk indicates statistical significance of the difference at P < 0.025 between the mean treatment and control values. In the first
experiment, rats were treated with 1.1 imol kg-' (0.5 mg kg-') intraperitoneally twice a week for 8 weeks (A and B). In the second experiment a dose of
2.2 gmol kg-' (1 mg kg-') was used (C and D). The R,R-Pt(DACH)CI4 enantiomer induced neurotoxicity after a cumulative dose of 13.2-17.6 lmol kg-', whereas
the S,S enantiomer did not until 30.8 gmol kg-'. The R,R enantiomer caused greater loss of body change than the S,S, relative to the control group
atmosphere. The cell lines were regularly checked for myco-
plasma infection. Cytotoxicity assessment was undertaken using
the sulphorhodamine B assay as described previously (Kelland et
al, 1992). Platinum complexes were dissolved in 0.9% sodium
chloride and added to cells in 96-well plates at concentrations
ranging from 0.001 to 100 tM for 96 h in quadruplicate. The IC50
was the drug concentration that reduced absorption (564 nm) of
sulphorhodamine B-stained wells to 50% of that of untreated
control wells.
RESULTS
Neurotoxicity of ormaplatin (Pt(DACH)CI4) and
oxaliplatin (Pt(DACH)oxalato) enantiomers
In the first experiment, rats were given R,R- or S,S-Pt(DACH)CI4
enantiomers at 1.1 ,Imol kg-' (0.5 mg kg-') twice a week for 8
weeks, and sensory nerve conduction velocity was assessed once a
week (Figure 2A and B and Table 1). Pt(R,R-DACH)CI4 induced
slowing of sensory nerve conduction velocity (-11.8% of mean
control SNCV; P < 0.002) after 6 weeks' treatment, at a cumula-
tive dose of 13.2 ,umol kg-' (6 mg kg-'). There was no slowing of
sensory nerve conduction velocity in animals treated for 8 weeks
with Pt(S,S-DACH)CI4 at this dose level. There was no drug-
induced moribundity in either treatment group, but anaesthetic-
related deaths accounted for the loss of two animals from the
Pt(R,R-DACH)C14 group at weeks 0 and 1, and one animal from
the control group at week 7. The control animals gained weight by
19.7% oftheir starting weight between weeks 0 and 8 (Figure 2B).
At the end ofthe experiment, the mean body weight ofthe Pt(R,R-
DACH)Cl4 group was lower than that of the controls (-7.4% of
mean control body weight at week 8; P = 0.003), whereas the
mean body weight of the Pt(S,S-DACH)CI4-treated group was
similar to that in the controls.
In the second experiment, rats were given Pt(DACH)CI4 enan-
tiomers at a higher dose of2.2 ,umol kg-' (1 mg kg-') twice a week
for 8 weeks (Figure 2C and D; and Table 1). The R,R enantiomer
of Pt(DACH)CI4 caused neurotoxicity (-19.9% of mean control
SNCV; P = 0.019) after only 4 weeks' treatment at a cumulative
dose of 17.6 gmol kg-' (8 mg kg-'). Pt(S,S-DACH)C14 did not
cause slowing of sensory nerve conduction velocity until week 7
(-22.7% of mean control SNCV; P = 0.004) after a cumulative
dose of 30.8 gmol kg-' (14 mg kg-'). Three of 12 animals from the
Pt(R,R-DACH)CI4 group had to be killed because ofdrug-induced
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Table 1 Stereoselective peripheral sensory neurotoxicity, body weight change and moribundity in rats treated with R,R- and S,S-Pt(DACH) enantiomers related
to ormaplatin and oxaliplatin
Isomer Dosea Time to development Cumulative Body Drug-induced
(gmol kg-') of neurotoxicity neurotoxic doseb weight moribundityd
[mg kg-'] (weeks) (,umol kg-') changec (%)
Pt(DACH)CI4 R,R- 1.1 [0.5] 6 13.2 -7.4e,f 0/12
S,S- >8 > 17.6 -1.0 0/12
R,R- 2.2 [1] 4 17.6 -20.3ef 3/12
S,S- 7 30.8 -5.7 0/12
Pt(DACH)oxalato R,R- 2.5 [1] 3 15.0 -9.1ef 0/12
S,S- 7 35.0 -5.7 0/12
Pt(DACH)CI2 R,R- 2.6 [1] 5 26.0 -24.8ef 4/12
S,S- 6 31.2 -17.9e 0/12
R,R enantiomers of Pt(DACH)CI4, Pt(DACH)oxalato and Pt(DACH)CI2, induced peripheral sensory neurotoxicity at significantly lower cumulative doses (18 + 5.7
vs 32 ± 2.3 ,umol kg-'; P < 0.01) and earlier during repeated-dose treatment (4 ± 1 vs 6.7 ± 0.6 weeks; P = 0.016) than did the S,S enantiomers. Body weight
change was significantly greater with R,Renantiomers (P < 0.02). aDose given twice a week intraperitoneally for 8 weeks. bCumulative dose at onset of
statistically significant difference in mean sensory nerve conduction velocity between treated and control age-matched animals. cDifference between mean body
weight in treated and control age-matched animals at week 8. dNumber of animals having to be killed because of drug-induced toxicity/total number treated.
eStatistically different compared with control group at P < 0.005. 'Statistically different compared with S,S group at P < 0.02.
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Figure 3 Platinum concentrations in dorsal root ganglia (DG), sciatic nerve (SN), spinal cord (SC) and brain (BR) from rats after 8 weeks' repeated treatment
with RR- or S,S-Pt(DACH)CI4, Pt(DACH)oxalato and Pt(DACH)CI2 enantiomers. Tissue samples were collected 7 days after the final dose (n = 4-6)
toxicity between 6 and 8 weeks. None of the Pt(S,S-DACH)C14
group exhibited severe constitutional toxicity. The mean body
weight ofPt(R,R-DACH)C14-treated animals at week 8 was lower
than that in controls (-20.3% ofmean control body weight at week
8; P < 0.001). The Pt(S,S-DACH)C14-treated rats showed no statis-
tically significant change in body weight compared with controls.
The R,R enantiomer ofPt(R,R-DACH)oxalato given at 1 mg kg-'
(2.5 ,umol kg-') twice a week induced neurotoxicity (-19.9% of
mean control SNCV; P = 0.02) after only 3 weeks treatment
and a cumulative dose of 15.0 ,mol kg-' (Table 1). The Pt(S,S-
DACH)oxalato enantiomer caused neurotoxicity (-17.7% of mean
control SNCV; P = 0.01) after 7 weeks' treatment and a cumulative
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Table 2 Cytotoxicity (IC50, gMa) of R, and S,S enantiomers of Pt(DACH)C04, Pt(DACH)oxalato and Pt(DACH)C12 against human ovarian carcinoma cell lines
in vitro
Pt(DACH)CI4 Pt(DACH)oxalato Pt(DACH)CI2
R,R- S,S- R,R- S,S- R,R- S,S-
41M 1.45 ±0.17 (6) 1.67 ±0.16 (6) 3.64 ± 1.10 (5) 3.84 ± 1.00 (5) 2.8± 0.8 (4) 2.3± 0.3 (4)
41M-cisR 1.80 ± 0.36 (6) 2.60 ± 0.21 (5) 6.03 ± 1.10 (4) 8.30 ± 0.66 (4) 4.8 ± 2.6 (4) 3.4± 1.8 (4)
CH1 0.21 ± 0.05b (5) 0.39 ± 0.02 (6)b 0.51 ± 0.18 (6) 1.04 ± 0.19 (5) 0.13± 0.03 (3) 0.36 ± 0.09 (3)
CH1-cisR 0.29 ± 0.14 (4) 0.78 ± 0.34 (4) 0.90± 0.11 (5) 2.64 ± 0.66 (5) 1.1 ± 0.55 (3) 3.3 ± 1.8 (3)
SKOV-3 8.80 ± 2.52 (6) 7.62 ± 0.67 (6) 13.6 ± 2.85 (5) 20.2 ± 2.01 (5) 18 ± 6.5 (3) 30 ± 2.5 (3)
aMean ± standard error of the mean (n). bDifference between the mean IC50 of R,Rand S,S isomer significant at P < 0.05.
dose of 35 jmol kg-'. The Pt(R,R-DACH)oxalato group showed
significant body weight change (-9.1% of mean control body
weight at week 8; P < 0.001) whereas the Pt(S,S-DACH)oxalato
group did not show any significant change in body weight
compared with controls.
Neurotoxicity of Pt(DACH) metabolites (Pt(DACH)CI2
and Pt(DACH)methionine enantiomers)
Pt(R,R-DACH)CI2 induced neurotoxicity (-13.0% ofmean control
SNCV; P <0.001) after5 weeks' treatment at a cumulative dose of
26 jmol kg-', whereas its S,S enantiomer induced neurotoxicity
(-17.3% of mean control SNCV; P = 0.002) after 6 weeks and a
cumulative dose of 31.2 gmol kg-'. Body weight change and
moribundity were more marked in the Pt(R,R-DACH)C12 group
(-8.7% of mean Pt(S,S-DACH)CI2 body weight at week 8;
P < 0.01). Rats treated with Pt(DACH)methionine enantiomers
showed no drug-induced moribundity, peripheral neurotoxicity or
body weight change compared with the control group.
Summary of neurotoxicity assessment
The data above indicate that R,R enantiomers of Pt(DACH)CI4,
Pt(DACH)oxalato and Pt(DACH)CI2, induce peripheral sensory
neurotoxicity at significantly lower cumulative doses (18 ± 5.7 vs
32 ± 2.3 ,umol kg-'; P < 0.01) and at earlier times (4 ± 1 vs
6.7 + 0.6 weeks; P = 0.016) during repeated dose treatment than
the S,S enantiomers. The Pt(DACH)methionine enantiomers
showed no biological activity.
Platinum concentrations in rat tissue and blood
Blood and tissues were collected from treated rats at the end ofthe
experiment (7 days after the final dose and 3 days after the final
nerve conduction velocity recording) and analysed for platinum
content by ICP-MS. Platinum concentrations in sciatic nerve,
dorsal root ganglia, spinal cord and brain from rats treated for 8
weeks with Pt(DACH) enantiomers are shown in Figure 3. The
neural tissue weights were similar between groups despite the
differences in degree oftreatment inducedbody weight loss. Tissue
platinum levels after treatment for 8-weeks with Pt(DACH)methio-
nine enantiomers ranged from 2 to 6 ng g-' (data not shown) but
were 100-fold lower than those taken from rats treated with the
other Pt(DACH) analogues (Figure 3). There was no enantiomeric
selectivity in the platinum concentrations in sciatic nerve, dorsal
root ganglia, spinal cord and brain, despite differences between
Pt(DACH) enantiomers in the degree of peripheral sensory neuro-
toxicity. All treatment groups showed preferential distribution of
platinum to peripheral neural tissues (sciatic nerve and dorsal root
ganglia) vs the central nervous system (brain, spinal cord). The
extent to which platinum concentrations were higher in the periph-
eral vs central nervous system was similar for both R,R (median
12.9-fold; range 5.2- to 32-fold) and S,S enantiomer (median
16-fold; range 2.5- to 31-fold) treated rats (P = 0.46). There was no
enantiomeric-selective difference in the mean platinum concentra-
tions found in whole blood (range 0.47-2.4 ,ug ml-') or blood
plasma (range 0.1-0.72 ,ug ml-') at the end ofthe 8 week treatment
period (data not shown) despite differences between enantiomers in
the degree of constitutional toxicity. Tissue-plasma ratios of plat-
inum concentrations in sciatic nerve (range 0.57-3.5) and dorsal
root ganglia (range 0.27-5.1) were similar after treatment withR,R-
and S,S-Pt(DACH) enantiomers (P = 0.34).
In vitro anti-tumour activity of Pt(DACH) enantiomers
The in vitro anti-tumour activity of Pt(DACH) enantiomers
was assessed against five human ovarian carcinoma cell lines.
The Pt(DACH)methionine enantiomers were inactive in vitro
(IC50> 100gM) in all cell lines (data not shown). The cytotoxicity
data for enantiomers of Pt(DACH)C14, Pt(DACH)oxalato and
Pt(DACH)C12 are shown in Table 2. The 41M pair of cell lines
exhibited no chiral discrimination in their sensitivity to R,R- or
S,S-Pt (DACH) enantiomers. The CH-1 pair ofcell lines showed a
trend of greater sensitivity (1.9- to 3-fold) to R,R enantiomers, but
the differences between enantiomers reached statistical signifi-
cance on only one occasion (Pt(DACH)CI4 enantiomers in the
CH-1 parent line). The SKOV-3 showed a small (0.9- to 1.6-fold),
inconsistent and statistically insignificant trend towards greater
sensitivity to R,R enantiomer. Together, these data suggest modest
and cell type-dependent enantiomeric selectivity of the anti-
tumour activity ofPt(DACH) deriviatives in vitro.
DISCUSSION
Considerable interest has recently surrounded the early-phase clin-
ical trials of ormaplatin and oxaliplatin because of their potential
for activity against resistant tumours (Wilkoff et al, 1987).
Ormaplatin and oxaliplatin contain a lipophilic DACH carrier
ligand that has two chiral centres and three possible isomeric
forms. A racemic mixture oformaplatin was developed because of
only minor differences between R,R and S,S isomers in their solu-
bility, stability and anti-tumour activity (Anderson et al, 1986)
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whereas oxaliplatin is the pure R,R enantiomer of
Pt(DACH)oxalato (Kidani et al, 1978). Both of these Pt(DACH)
derivatives undergo extensive metabolism in biological systems
(Maudlin et al, 1988; Gibbons et al, 1989; Chaney et al, 1990;
Carfagna et al, 1991; Pendyala and Creaven, 1993; Petros et al,
1994). Early-phase clinical trials of ormaplatin and oxaliplatin
encountered severe and dose-limiting peripheral neurotoxicity,
associated with sensory ataxia and walking difficulties in some
patients, related to the cumulative dose (Extra et al 1990; Schilder
et al 1994). We hypothesized that the peripheral sensory neurotox-
icity associated with these Pt(DACH) derivatives may vary in rela-
tion to their biotransformation and the enantiomeric configuration
of the DACH ligand. In the studies described, we prepared pure
R,R and S,S enantiomers oformaplatin (Pt(DACH)CI4), oxaliplatin
(Pt(DACH)oxalato) and their major biotransformation products
(Pt(DACH)CI2 and Pt(DACH)methionine) with the specific aims
of comparing the peripheral sensory neurotoxicity and tissue
distribution of platinum in rats after repeat-dose treatment and
their in vitro activity against human ovarian carcinoma cell lines.
These studies, and our previous work (McKeage et al, 1994),
demonstrate a limited range by which platinum derivatives reduce
peripheral sensory nerve conduction velocity in rats during
repeated treatment, from 0 to 25% reduction in conduction
velocity relative to age-matched control animals. Cisplatin causes
selective toxicity to a subset ofperipheral sensory neurons that are
characterized as fast-conducting, large-diameter, myelinated fibres
and by being involved in proprioceptive function (Thompson et al,
1984; Cavaletti et al, 1992). Other neurons, by comparison, are
resistant to platinum toxicity, e.g. small-diameter, slow-conducting
nociceptive and thermoceptive sensory neurons and motor
neurons. It may be that the partial reduction in sensory nerve
conduction velocity induced by neurotoxic platinum complexes in
our rat model system represents damage to this subset of vulner-
able sensory fibres. In this way, platinum drug-induced toxicity in
the model system correlates with the selective deficits in vibration
sense, proprioception and sensory ataxia (and preservation of
motor, pain and thermoceptive function) observed in platinum
drug-treated human subjects (Thompson et al, 1984).
We found that both R,R and S,S enantiomers of ormaplatin and
oxaliplatin induced slowing of sensory nerve conduction during
repeated-dose treatment in rats but that the time and cumulative
dose to the development of neurotoxicity varied in relationship
to their stereochemistry. The Pt(R,R-DACH)C14 and Pt(R,R-
DACH)oxalato enantiomers induced peripheral sensory neuro-
toxicity in rats at earlier times and lower cumulative doses than
Pt(S,S-DACH)C14 and Pt(S,S-DACH)oxalato. Our previous
studies (McKeage et al, 1994) of the clinical preparation of
ormaplatin [racemic mixture of Pt(R,R-DACH)C14 and Pt(S,S-
DACH)C14 defined a cumulative dose at the onset of peripheral
neurotoxicity (26 ,umol kg-') in rats that was intermediate between
those we now report for the pure enantiomers (13-18 vs 31 rmol
kg-'). In this way, our results suggest that the Pt(R,R-DACH)C14
enantiomer may have been the most neurotoxic constituent of the
ormaplatin racemate recently withdrawn from clinical trial, and
that the S,S isomers of ormaplatin and oxaliplatin may be inter-
esting candidates for future clinical trial.
The Pt(DACH)methionine ormaplatin biotransformation
product exhibited no biological activity in vivo and in vitro, and
low tissue platinum concentrations in our studies. It may be that
the Pt(DACH)methionine complex was transported poorly across
biological membranes as methionine is charged at physiological
pH (PKa = 2.28). The Pt(DACH)CI2 biotransformation product
caused greater body weight loss and showed less neurotoxic chiral
discrimination than the Pt(DACH)CI4 and Pt(DACH)oxalato enan-
tiomers. In this way, the enantiomeric-selective neurotoxic action
of Pt(DACH) derivatives may vary in relation to dose and the
degree of constitutional toxicity. The significantly greater body
weight loss in rats treated with R,R enantiomers may be due to
stereoselective toxicity in gastrointestinal tissues.
We measured platinum concentrations in nervous tissue and
blood collected from rats at the end of each experiment following
the completion of an 8-week repeat-dose treatment course. We
found no enantiomeric selectivity in the accumulation of platinum
in dorsal root ganglia, sciatic nerves, spinal cord or brain despite
the differences between Pt(DACH) enantiomers in the degree of
peripheral neurotoxicity. Drugs accumulate in the body during
multiple dosing and reach steady-state concentrations (Css) at
a time and level determined by the dose rate and elimination
rate [Css (amount/vol) = dose rate (amount/unit time)/clearance
(amount/volume)], and steady-state levels are usually reached
after 4-5 half-lives (Rowland and Tozer, 1989). In our studies,
Pt(DACH) enantiomers were given at the same dose rate within
each experiment and platinum concentrations in tissues after 8
weeks' treatment were similar for R,R and S,S isomers. It may be
that the elimination half-life of platinum in neural tissue is less
than 12 days and that steady-state concentrations had already been
reached before 8 weeks. Gregg et al (1992), studied platinum
concentrations in neurological tissue taken after death from
cisplatin-treated humans and described a relationship between the
tissue accumulation of platinum and peripheral neurotoxicity
(Gregg et al, 1992). As in our study, they found preferential distri-
bution of platinum to peripheral vs central nervous tissues, but
tissue levels were two- to fourfold higher than in our rats even
though we used more toxic platinum derivatives. It may be that
there were significant differences in tissue platinum concentrations
at early time points that accounted for the change in nerve conduc-
tion observed, or that the neurotoxicity of platinum derivatives is
not directly caused by the neural accumulation of elemental plat-
inum. As our tissue sampling was destructive it was not possible to
assess the time course oftissue platinum concentrations, but this is
an interesting possible topic for future study.
We compared the in vitro activity of R,R- and S,S-Pt(DACH)
enantiomers against a series ofhuman ovarian carcinoma cell lines
with defined resistance mechanisms to cisplatin (Kelland et al,
1992; Walton et al, 1996). Three cell lines (41M, 41McisR and
SKOV-3) exhibited no (or inconsistent) chiral discrimination
between R,R and S,S enantiomers ofbiologically active Pt(DACH)
derivatives. In contrast, the CH-1 and CH-lcisR lines exhibited a
consistent trend towards stereoselective activity favouring the R,R
enantiomers (more active). In this way, our findings are consistent
with other reports of modest and cell line-dependent enantiomeric
selectivity of the anti-tumour activity of Pt(DACH) isomers
(Kidani et al, 1978; Vollano et al, 1987; Kido et al, 1993; Siddik et
al, 1993). The CH-1 and CH-lcisR cells contain functionally wild-
type p53 compared with the 41M, 41McisR and SKOV-3, in which
the p53 gene is mutated or deleted (Walton et al, 1996). The p53
gene product is expressed in response to platinum drug-induced
DNA damage, induces delayed cell transit through the GI phase
and may effect the repair of the drug-induced DNA lesions
(Shimamura and Fisher, 1996). It may be that DNA-bound
Pt(DACH) enantiomers interact in a stereoselective way with
proteins involved in the repair of DNA damage. In this way,
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Pt(DACH) enantiomers might exhibit stereoselective activity in
cells with intact p53-related DNA repair mechanisms (CH-1 and
CH-lcisR) but not in those with defective p53 pathways (41M,
41McisR and SKOV-3).
In conclusion, we found enantiomeric-selective peripheral
sensory neurotoxicity of Pt(DACH) derivatives in rats during
repeated-dose treatment, favouring S,S isomers (less toxic), but
less chiral discrimination in their in vitro anti-tumour activity.
There may be stereoselective interactions between Pt(DACH)
derivatives and target molecules in large-diameter proprioceptive
neurons that accounts for their enantiomeric-selective neuro-
toxicity, as the accumulation in these tissues was similar. The
anti-tumour action of the platinum derivatives involves the cross-
linking of nuclear DNA, block of the mitotic cell cycle and the
induction ofapoptosis (Sorenson et al, 1990). Another toxic mech-
anism may underlie their damage to proprioceptive neurons, as
these are post-mitotic cells and other workers have found no plat-
inum-induced DNA modifications in dorsal root ganglion neurons
from treated rats using antiserum against the drug-DNA lesion
(Terheggen et al, 1989).
ABBREVIATIONS
DACH, 1,2-diaminocyclohexane; ICP-MS, inductively coupled
plasma mass spectrometry; ormaplatin, rac-cyclohexane-1,2-
diamminetetrachloroplatinum(IV); oxaliplatin, (R,R)-cyclo-
hexane-1,2-diammineoxalatoplatinum(II); SNCV, sensory nerve
conduction velocity.
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